AZD0780 is an orally bioavailable small molecule PCSK9 inhibitor that binds the C-terminal domain of PCSK9. It disrupts lysosomal trafficking of the PCSK9-LDLR complex to prevent LDL receptor degradation, making it a valuable research tool for investigating hypercholesterolemia in both cellular and animal models.